334 related articles for article (PubMed ID: 32332015)
1. The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures.
Chen L; Oke T; Siegel N; Cojocaru G; Tam AJ; Blosser RL; Swailes J; Ligon JA; Lebid A; Morris C; Levin A; Rhee DS; Johnston FM; Greer JB; Meyer CF; Ladle BH; Thompson ED; Montgomery EA; Choi W; McConkey DJ; Anders RA; Pardoll DM; Llosa NJ
Clin Cancer Res; 2020 Aug; 26(15):4018-4030. PubMed ID: 32332015
[TBL] [Abstract][Full Text] [Related]
2. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13
Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y
Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519
[TBL] [Abstract][Full Text] [Related]
3. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
4. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
[TBL] [Abstract][Full Text] [Related]
5. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer.
Sofopoulos M; Fortis SP; Vaxevanis CK; Sotiriadou NN; Arnogiannaki N; Ardavanis A; Vlachodimitropoulos D; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2019 Nov; 68(11):1733-1745. PubMed ID: 31598757
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
8. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
[TBL] [Abstract][Full Text] [Related]
9. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
Wang S; Xie K; Liu T
Front Immunol; 2021; 12():690112. PubMed ID: 34367148
[TBL] [Abstract][Full Text] [Related]
10. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
Tang H; Qiu X; Timmerman C; Fu YX
Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in Sarcoma: Current Data and Promising Strategies.
Wood GE; Meyer C; Petitprez F; D'Angelo SP
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432234. PubMed ID: 38781557
[TBL] [Abstract][Full Text] [Related]
13. Existence of intratumoral tertiary lymphoid structures is associated with immune cells infiltration and predicts better prognosis in early-stage hepatocellular carcinoma.
Li H; Wang J; Liu H; Lan T; Xu L; Wang G; Yuan K; Wu H
Aging (Albany NY); 2020 Feb; 12(4):3451-3472. PubMed ID: 32087064
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer.
Schweiger T; Berghoff AS; Glogner C; Glueck O; Rajky O; Traxler D; Birner P; Preusser M; Klepetko W; Hoetzenecker K
Clin Exp Metastasis; 2016 Oct; 33(7):727-39. PubMed ID: 27449756
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
16. The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.
Hildebrand KM; Singla AK; McNeil R; Marritt KL; Hildebrand KN; Zemp F; Rajwani J; Itani D; Bose P; Mahoney DJ; Jirik FR; Monument MJ
PLoS One; 2021; 16(7):e0253864. PubMed ID: 34242269
[TBL] [Abstract][Full Text] [Related]
17. Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma.
Rodriguez AB; Peske JD; Engelhard VH
Methods Mol Biol; 2018; 1845():241-257. PubMed ID: 30141017
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.
Goc J; Germain C; Vo-Bourgais TK; Lupo A; Klein C; Knockaert S; de Chaisemartin L; Ouakrim H; Becht E; Alifano M; Validire P; Remark R; Hammond SA; Cremer I; Damotte D; Fridman WH; Sautès-Fridman C; Dieu-Nosjean MC
Cancer Res; 2014 Feb; 74(3):705-15. PubMed ID: 24366885
[TBL] [Abstract][Full Text] [Related]
19. High infiltration of B cells in tertiary lymphoid structures, TCR oligoclonality, and neoantigens are part of esophageal squamous cell carcinoma microenvironment.
Barros LRC; Souza-Santos PT; Pretti MAM; Vieira GF; Bragatte MAS; Mendes MFA; De Freitas MV; Scherer NM; De Oliveira IM; Rapozo DCM; Fernandes PV; Simão TA; Soares-Lima SC; Boroni M; Ribeiro Pinto LF; Bonamino MH
J Leukoc Biol; 2020 Oct; 108(4):1307-1318. PubMed ID: 32827331
[TBL] [Abstract][Full Text] [Related]
20. CD86
Wennhold K; Thelen M; Lehmann J; Schran S; Preugszat E; Garcia-Marquez M; Lechner A; Shimabukuro-Vornhagen A; Ercanoglu MS; Klein F; Thangarajah F; Eidt S; Löser H; Bruns C; Quaas A; von Bergwelt-Baildon M; Schlößer HA
Cancer Immunol Res; 2021 Sep; 9(9):1098-1108. PubMed ID: 34155067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]